HER1-based vaccine: simultaneous activation of humoral and cellular immune response

Publication date: Available online 31 May 2018

Source: Seminars in Oncology

Author(s): Gretchen Bergado Báez, Diana R. Hernández Fernández, Zaima Mazorra Herrera, Belinda Sánchez Ramírez

Abstract

The human epidermal growth factor receptor 1 (HER1) is a tumor associated antigen that has been validated as a clinical target for several passive, non-immune therapies currently approved for the treatment epithelial tumors. HER1 is an oncogene that not only promotes tumor progression and survival, but also immune-escape. Its overexpression in some epithelial malignancies has been correlated with a poor prognosis. We developed an approach to target HER1 by specific active immunotherapy, recognizing the extracellular domain of the receptor, using a combination of VSSP and Montanide ISA 51 as adjuvants. We summarize the results obtained with this vaccine in both the preclinical and clinical settings, emphasizing the importance of the induction of both humoral and cellular responses for the success of cancer vaccines, as safe therapeutic alternatives for the treatment of cancer.

https://ift.tt/2KNuB3f